Genmab A/S
CSE:GMAB

Watchlist Manager
Genmab A/S Logo
Genmab A/S
CSE:GMAB
Watchlist
Price: 1 483.5 DKK 2.49% Market Closed
Market Cap: 97.7B DKK
Have any thoughts about
Genmab A/S?
Write Note

Genmab A/S
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Genmab A/S
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
Genmab A/S
CSE:GMAB
Income from Continuing Operations
kr5.5B
CAGR 3-Years
30%
CAGR 5-Years
36%
CAGR 10-Years
45%
Zealand Pharma A/S
CSE:ZEAL
Income from Continuing Operations
-kr1.1B
CAGR 3-Years
0%
CAGR 5-Years
-16%
CAGR 10-Years
-37%
Ascendis Pharma A/S
NASDAQ:ASND
Income from Continuing Operations
-€489.5m
CAGR 3-Years
-2%
CAGR 5-Years
-22%
CAGR 10-Years
N/A
B
Bavarian Nordic A/S
CSE:BAVA
Income from Continuing Operations
kr707.4m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
F
Fluoguide AS
STO:FLUO
Income from Continuing Operations
-kr38.4m
CAGR 3-Years
-30%
CAGR 5-Years
-273%
CAGR 10-Years
N/A
Bioporto A/S
CSE:BIOPOR
Income from Continuing Operations
-kr50m
CAGR 3-Years
6%
CAGR 5-Years
0%
CAGR 10-Years
-10%
No Stocks Found

Genmab A/S
Glance View

Market Cap
94.2B DKK
Industry
Biotechnology

Genmab A/S is a cutting-edge biotechnology company based in Denmark, renowned for its pioneering approach to developing differentiated antibody therapies for the treatment of cancer. Founded in 1999, the company focuses on harnessing the power of the immune system to combat various malignancies. Its flagship product, Darzalex (daratumumab), has transformed treatment protocols for multiple myeloma, achieving robust sales and establishing Genmab as a formidable player in the oncology landscape. The company's innovative platform combines proprietary technologies and skilled teams to create next-generation therapies, underscoring its commitment to improving patients' lives through targeted and effective cancer treatment solutions. As Genmab continues to build on its success, it is also expanding its pipeline with a diverse array of promising assets in various stages of clinical development. Not only does this validate its research capabilities, but it also positions Genmab for substantial future growth. The company's strategic collaborations with major pharmaceutical partners, such as Johnson & Johnson, further amplify its reach and resource capabilities, fostering a collaborative approach to accelerate drug development. With a solid financial standing and a focus on sustained innovation, Genmab A/S presents an intriguing investment opportunity for those looking to tap into the evolving landscape of biotechnology and oncology therapeutics.

GMAB Intrinsic Value
2 507.16 DKK
Undervaluation 41%
Intrinsic Value
Price

See Also

What is Genmab A/S's Income from Continuing Operations?
Income from Continuing Operations
5.5B DKK

Based on the financial report for Jun 30, 2024, Genmab A/S's Income from Continuing Operations amounts to 5.5B DKK.

What is Genmab A/S's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
45%

Over the last year, the Income from Continuing Operations growth was 16%. The average annual Income from Continuing Operations growth rates for Genmab A/S have been 30% over the past three years , 36% over the past five years , and 45% over the past ten years .

Back to Top